These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33145806)

  • 1. PRDM1 decreases sensitivity of human NK cells to IL2-induced cell expansion by directly repressing CD25 (IL2RA).
    Akman B; Hu X; Liu X; Hatipoğlu T; You H; Chan WC; Küçük C
    J Leukoc Biol; 2021 May; 109(5):901-914. PubMed ID: 33145806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.
    Sim GC; Liu C; Wang E; Liu H; Creasy C; Dai Z; Overwijk WW; Roszik J; Marincola F; Hwu P; Grimm E; Radvanyi L
    Cancer Immunol Res; 2016 Nov; 4(11):983-994. PubMed ID: 27697858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRDM1 is a tumor suppressor gene in natural killer cell malignancies.
    Küçük C; Iqbal J; Hu X; Gaulard P; De Leval L; Srivastava G; Au WY; McKeithan TW; Chan WC
    Proc Natl Acad Sci U S A; 2011 Dec; 108(50):20119-24. PubMed ID: 22143801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.
    Gubbels JA; Gadbaw B; Buhtoiarov IN; Horibata S; Kapur AK; Patel D; Hank JA; Gillies SD; Sondel PM; Patankar MS; Connor J
    Cancer Immunol Immunother; 2011 Dec; 60(12):1789-800. PubMed ID: 21792658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells.
    Jounaidi Y; Cotten JF; Miller KW; Forman SA
    Cancer Res; 2017 Nov; 77(21):5938-5951. PubMed ID: 28916655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of IL12 and IL2 on expression and function of cellular adhesion molecules on purified human natural killer cells.
    Rabinowich H; Herberman RB; Whiteside TL
    Cell Immunol; 1993 Dec; 152(2):481-98. PubMed ID: 7903063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3.
    Takahara M; Kis LL; Nagy N; Liu A; Harabuchi Y; Klein G; Klein E
    Int J Cancer; 2006 Dec; 119(12):2775-83. PubMed ID: 17013900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome wide transcriptional analysis of resting and IL2 activated human natural killer cells: gene expression signatures indicative of novel molecular signaling pathways.
    Dybkaer K; Iqbal J; Zhou G; Geng H; Xiao L; Schmitz A; d'Amore F; Chan WC
    BMC Genomics; 2007 Jul; 8():230. PubMed ID: 17623099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
    Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The downregulation of PRDM1/Blimp-1 is associated with aberrant expression of miR-223 in extranodal NK/T-cell lymphoma, nasal type.
    Liang L; Nong L; Zhang S; Zhao J; Ti H; Dong Y; Zhang B; Li T
    J Exp Clin Cancer Res; 2014 Jan; 33(1):7. PubMed ID: 24438193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells.
    Pahl JHW; Koch J; Götz JJ; Arnold A; Reusch U; Gantke T; Rajkovic E; Treder M; Cerwenka A
    Cancer Immunol Res; 2018 May; 6(5):517-527. PubMed ID: 29514797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy.
    Tong B; Leong SG; Jian T; Niu G; Gai Y; Meng X; Lv H; Dong X; Ding X; Chen J
    Int Immunopharmacol; 2024 Jul; 136():112359. PubMed ID: 38815348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-2-dependent adaptive control of NK cell homeostasis.
    Gasteiger G; Hemmers S; Bos PD; Sun JC; Rudensky AY
    J Exp Med; 2013 Jun; 210(6):1179-87. PubMed ID: 23650439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRDM1/Blimp-1 controls effector cytokine production in human NK cells.
    Smith MA; Maurin M; Cho HI; Becknell B; Freud AG; Yu J; Wei S; Djeu J; Celis E; Caligiuri MA; Wright KL
    J Immunol; 2010 Nov; 185(10):6058-67. PubMed ID: 20944005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic manipulation of primary human natural killer cells to investigate the functional and oncogenic roles of PRDM1.
    Dong G; Li Y; Lee L; Liu X; Shi Y; Liu X; Bouska A; Gong Q; Kong L; Wang J; Lou CH; McKeithan TW; Iqbal J; Chan WC
    Haematologica; 2021 Sep; 106(9):2427-2438. PubMed ID: 32732362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study.
    Ingram W; Chan L; Guven H; Darling D; Kordasti S; Hardwick N; Barber L; Mufti GJ; Farzaneh F
    Br J Haematol; 2009 Jun; 145(6):749-60. PubMed ID: 19388935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole transcriptome analysis reveals dysregulated oncogenic lncRNAs in natural killer/T-cell lymphoma and establishes MIR155HG as a target of PRDM1.
    Baytak E; Gong Q; Akman B; Yuan H; Chan WC; Küçük C
    Tumour Biol; 2017 May; 39(5):1010428317701648. PubMed ID: 28468592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-HDAC inhibitors augment IL2-induced proliferation of NK cells via the JAK2-STAT5B signaling pathway.
    Zheng J; Lu Y; Xiao J; Duan Y; Zong S; Chen X; Hu T; Li L; Zhang Y
    Int Immunopharmacol; 2023 Mar; 116():109753. PubMed ID: 36738675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells.
    Kim JR; Mathew SO; Mathew PA
    Immunobiology; 2016 Jan; 221(1):31-9. PubMed ID: 26310579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.